Fig. 1From: Protocol for a double-blind, randomized controlled trial on the dose-related efficacy of omalizumab in multi-food oral immunotherapyConceptual model of omalizumab-enabled immunotherapy. ED50: Eliciting does triggering 50% of degranulation; IgE: immunoglobulin E; OIT: oral immunotherapyBack to article page